Clinical efficacy of membrane-free stem cell extracts for the treatment of canine atopic dermatitis

Kim Ys, Ha Se, H Bae, D Lee, Yu Dh and Kim Gs
Additional contact information
Kim Ys: T-stem Co., Ltd., Changwon, Gyeongsangnam-do, Republic of Korea
Ha Se: Research Institute of Life Science and College of Veterinary Medicine, Gyeongsang National University, Jinju-daero, Jinju, Republic of Korea
H Bae: College of Veterinary Medicine, Gyeongsang National University, Jinju-daero, Jinju, Republic of Korea
D Lee: College of Veterinary Medicine, Gyeongsang National University, Jinju-daero, Jinju, Republic of Korea
Yu Dh: College of Veterinary Medicine, Gyeongsang National University, Jinju-daero, Jinju, Republic of Korea
Kim Gs: Research Institute of Life Science and College of Veterinary Medicine, Gyeongsang National University, Jinju-daero, Jinju, Republic of Korea

Veterinární medicína, 2022, vol. 67, issue 9, 463-470

Abstract: Despite various treatment options for canine atopic dermatitis (cAD), therapeutic limitations still exist, including adverse effects and low absorption ratios. This study evaluated the effects of a membrane-free stem cell extract (MFSCE) on the clinical signs of atopic dogs. Thirty client-owned dogs previously diagnosed with cAD were separated into placebo (n = 10) and MFSCE-treated groups (n = 20). The dogs were treated with a cream (MFSCE and placebo) via dermal administration twice daily for 14 days, and the clinical response was recorded on days 0, 7, and 14. The MFSCE-treated group showed significantly decreased severity of pruritus on day 14 compared to that on day 0. In addition, the erythema, pigmentation, skin dryness, and thickness were remarkably decreased in the MFSCE-treated group on day 14 compared to those on day 0 whereas no significant changes were observed in the placebo-treated group. No general clinical signs or adverse effects were observed in this study. These results suggest that MFSCE could be a surrogate treatment option for cAD.

Keywords: atopic dermatitis; canine; clinical trial; membrane-free stem cell extract (MFSCE); veterinary medicine (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://vetmed.agriculturejournals.cz/doi/10.17221/136/2021-VETMED.html (text/html)
http://vetmed.agriculturejournals.cz/doi/10.17221/136/2021-VETMED.pdf (application/pdf)
free of charge

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:caa:jnlvet:v:67:y:2022:i:9:id:136-2021-vetmed

DOI: 10.17221/136/2021-VETMED

Access Statistics for this article

Veterinární medicína is currently edited by Ing. Helena Smolová Ph.D.

More articles in Veterinární medicína from Czech Academy of Agricultural Sciences
Bibliographic data for series maintained by Ivo Andrle ().